
News|Articles|April 1, 2011
FDA Pipeline Preview, April 2011 (Salix, Protalix, Amyvid, indacaterol, Istodax, Mucin 1 targeting peptide GO-203-2c, Intercept plasma, Lomitapide, Liver cell therapy)
Recent FDA action (through, March 2011) related to Salix, Protalix, Amyvid, indacaterol, Istodax, Mucin 1 targeting peptide GO-203-2c, Intercept plasma, Lomitapide, Liver cell therapy.
Advertisement
Complete response
Recommendations for approval
Priority review
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
ACIP to vote on major hepatitis B vaccine update that could reshape the childhood vaccine schedule
2
Transplant-fueled hybrid immune systems may help reverse Type 1 diabetes
3
ACIP votes to end universal birth-dose for hepatitis B vaccine with updated guidance for parents and doctors
4
New test may solve the specificity and false-positive problems of the PSA test for prostate cancer
5





















































